Abcam to Open Office in Shanghai, China to Support Chinese Customers
Abcam plc, a global leader in the supply of innovative protein research tools, will open a new office in February 2014, in Shanghai, China. The new hub is the company’s ninth global office, and has been established to support Abcam’s focus on increasing geographic reach and improving distribution channels to rapidly growing markets.
Located in Zhangjiang Hi-Tech Park, Pudong New District, a prominent economic growth and innovation area, the office is within close proximity of the City and Abcam’s production facility in Hangzhou, which develops pioneering research tools such as RabMAb®, its proprietary rabbit monoclonal antibody technology.
The office will house customer and technical support functions, provided by native Mandarin speakers, as well as a product warehouse, which will facilitate local stock storage for the first time. This means that customers will benefit from improved delivery times, with the large majority of orders arriving at their door within 24 hours. The proximity of the office will also enable Abcam to support customers with more specific needs through its extensive range of products and services, including custom antibody production.
Dr Jonathan Milner, CEO, Abcam, said: “China is an important market for Abcam and we’re pleased to provide enhanced services such as faster delivery and dedicated local language support to our customers. Further future investments will ensure we continue to deliver innovative products and services to enable scientists to discover more.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance